LONDON (Alliance News) - Faron Pharmaceuticals Oy on Tuesday said it has filed a new patent application covering its Traumakine treatment in Finland.
The patent covers the Traumakine formulation for the intravenous treatment of acute respiratory distress syndrome.
"As of today, our Traumakine treatment is the only known intravenously administered human interferon-beta preparation and it is important that dosing is optimal for patients lacking peripheral circulation, as is the case with ARDS patients," said Chief Executive Markku Jalkanen.
"We have carefully tested various ingredients to optimise interferon-beta use in these patients and have now completed all necessary tests for patent purposes. If our claims are approved, we could have a proprietary product for the next two decades, further increasing Traumakine's significant, commercial potential," he added.
Faron shares were untraded on Tuesday morning, having last traded at 265.00 pence.
By Sam Unsted; samunsted@alliancenews.com; @SamUAtAlliance
Copyright 2016 Alliance News Limited. All Rights Reserved.
Faron Pharma (FARN)